Drug Products for Clinical Trials | FDA Approved Drugs List 2018

Date : 1st March 2018 to 2nd March 2018

Place : United States, boston, ma

Website :http://www.globalcompliancepanel.com/control/globalseminars/~product_id=901549SEMINAR?allconferencealerts-March-2018-SEO

Contact Person:Event Manager

Description:

Course "Different requirements for Phase I Investigational Drug Products: which GMPs apply since most Phase I drugs are exempt from full GMP requirements and what IND data requirements are necessary as a result?" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion. Overview: In January 2006, FDA issued a final rule which specified that most pharmaceutical products (including biologics) produced for use in Phase I clinical trial studies were exempted from complying with GMP requirements, as defined in 21 CFR Part 211 under 21 CFR 210.2(c). Section 501(a)(2)(B) of the FD&C Act requires drugs, including IND products, to comply with cGMPs or if they are not manufactured in compliance with cGMPs, they are deemed adulterated. Based on this statutory requirement for manufacturers to follow GMPs, FDA issued cGMP regulations for drug and biological products in the Code of Federal Regulations (in 21 CFR parts 210 and 211). There are certain requirements in 21 CFR Part 211 that are directed at the commercial manufacture of products typically characterized by large, repetitive, commercial batch production and requirements as a result, are not appropriate to the manufacture of most investigational drugs used for phase I clinical trials. Based on these issues, application of cGMPs to Phase I investigational drug products was exempted from 21 CFR 211. However, based on statutory requirements as given in Section 505(i) of the FD&C Act, FDA issued regulations governing IND products in order to protect human subjects enrolled in clinical trials, specifically with regards to the chemistry, manufacturing and controls data submitted as part of IND applications for drugs or biological products. Subsequent to FDAs final rule of January 2006, FDA released the Guidance for Industry, "INDs- Approaches to Complying with CGMP During Phase I". This document describes the CMC data necessary for inclusion in the IND. FDA reviews the IND to determine whether phase I investigational drugs to be used in the clinical trial to permit the trial to proceed, which is partially dependent on whether the product has the identity, strength, quality and purity and purported effect described in the IND application. FDA can chose to place the IND on clinical hold or could terminate the IND based on their review. If an IND is placed on clinical hold, the hold may be removed if the sponsor addresses the deficiencies, but clinical trials may not progress until the clinical hold is removed.

Drug Products for Clinical Trials | FDA Approved Drugs List 2018 will be held in boston, ma,United States on date 2018-03-02

---

Deadline for abstracts/proposals : 1st March 2018

Keynote Speakers : Stephanie Cooke President/CEO, Cooke Consulting Inc. Stephanie Cooke, is the President/CEO of Cooke Consulting, Inc. Stephanie uses her roughly 20 years of experience to provide global consulting services in various areas of Regulatory Affairs, Quality Assurance and validation for pharmaceutical, biological/biotech products, medical device, combination drug/device and nutraceutical firms. Her broad-based experience includes preparation of regulatory dossiers for human and animal pharmaceuti

Conference Highlights :Quality Associates or Specialists Regulatory Management or Regulatory Specialists Compliance professionals Quality Auditors Validation Engineers R & D Scientists- chemists, geneticists, biochemistry specialists, formulation chemistry Laboratory Personnel Senior Quality Managers, Quality VPs

Venue :Boston, MA, United States

Check the event website for more details.